Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 13/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CSNK1D | P48730 | 5/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 5/20 | 0.41 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2069222 | 1.00 | KCNH2 (0.68) | KCNH2CYP3A4CSNK1DCSNK1ETGFBR1 | |
| SCHEMBL2069305 | 1.00 | KCNH2 (0.68) | KCNH2CYP3A4CSNK1DCSNK1ETGFBR1 | |
| SCHEMBL2068791 | 0.96 | KCNH2 (0.71) | KCNH2CYP3A4CSNK1DCSNK1ETGFBR1 | |
| SCHEMBL1049159 | 0.96 | KCNH2 (0.71) | KCNH2CYP3A4CSNK1DCSNK1ETGFBR1 | |
| SCHEMBL2068359 | 0.96 | KCNH2 (0.71) | KCNH2CYP3A4CSNK1DCSNK1ETGFBR1 | |
| SCHEMBL2068507 | 0.95 | KCNH2 (0.70) | KCNH2CYP3A4CSNK1DCSNK1ETGFBR1 | |
| SCHEMBL2069132 | 0.95 | KCNH2 (0.70) | KCNH2CYP3A4CSNK1DCSNK1ETGFBR1 | |
| SCHEMBL12952052 | 0.95 | KCNH2 (0.70) | KCNH2CYP3A4CSNK1DCSNK1ETGFBR1 | |
| SCHEMBL2068227 | 0.93 | KCNH2 (0.71) | KCNH2CYP3A4CSNK1DCSNK1ETGFBR1 | |
| SCHEMBL2069978 | 0.93 | KCNH2 (0.71) | KCNH2CYP3A4CSNK1DCSNK1ETGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059934-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-03-10 | — | — | US | disclosed |
| WO-2011006143-A2 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES | IRM LLC (BM) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059934-A1 | COMPOUNDS AND COMPOSITIONS USEFUL FOR THE TREATMENT OF PARASITIC DISEASES | SQLE, SGMS2, FDPS | KCNH2 2202/4885CYP3A4 221/4885CSNK1D 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.